These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 38843617)
21. LRRK2 activation in idiopathic Parkinson's disease. Di Maio R; Hoffman EK; Rocha EM; Keeney MT; Sanders LH; De Miranda BR; Zharikov A; Van Laar A; Stepan AF; Lanz TA; Kofler JK; Burton EA; Alessi DR; Hastings TG; Greenamyre JT Sci Transl Med; 2018 Jul; 10(451):. PubMed ID: 30045977 [TBL] [Abstract][Full Text] [Related]
22. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum. Westerlund M; Ran C; Borgkvist A; Sterky FH; Lindqvist E; Lundströmer K; Pernold K; Brené S; Kallunki P; Fisone G; Olson L; Galter D Mol Cell Neurosci; 2008 Dec; 39(4):586-91. PubMed ID: 18790059 [TBL] [Abstract][Full Text] [Related]
23. Garrido A; Fairfoul G; Tolosa ES; Martí MJ; Green A; Ann Clin Transl Neurol; 2019 Jun; 6(6):1024-1032. PubMed ID: 31211166 [TBL] [Abstract][Full Text] [Related]
24. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons. Bieri G; Brahic M; Bousset L; Couthouis J; Kramer NJ; Ma R; Nakayama L; Monbureau M; Defensor E; Schüle B; Shamloo M; Melki R; Gitler AD Acta Neuropathol; 2019 Jun; 137(6):961-980. PubMed ID: 30927072 [TBL] [Abstract][Full Text] [Related]
25. LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. Huang Y; Song YJ; Murphy K; Holton JL; Lashley T; Revesz T; Gai WP; Halliday GM Acta Neuropathol; 2008 Dec; 116(6):639-46. PubMed ID: 18936941 [TBL] [Abstract][Full Text] [Related]
26. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Büeler H Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005 [TBL] [Abstract][Full Text] [Related]
27. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Smith WW; Pei Z; Jiang H; Moore DJ; Liang Y; West AB; Dawson VL; Dawson TM; Ross CA Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18676-81. PubMed ID: 16352719 [TBL] [Abstract][Full Text] [Related]
29. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology. Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL eNeuro; 2017; 4(2):. PubMed ID: 28321439 [TBL] [Abstract][Full Text] [Related]
30. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease. Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655 [TBL] [Abstract][Full Text] [Related]
31. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease. Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188 [TBL] [Abstract][Full Text] [Related]
32. Parkinson's disease in a dish - Using stem cells as a molecular tool. Badger JL; Cordero-Llana O; Hartfield EM; Wade-Martins R Neuropharmacology; 2014 Jan; 76 Pt A():88-96. PubMed ID: 24035919 [TBL] [Abstract][Full Text] [Related]
33. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease. Yonova-Doing E; Atadzhanov M; Quadri M; Kelly P; Shawa N; Musonda ST; Simons EJ; Breedveld GJ; Oostra BA; Bonifati V Parkinsonism Relat Disord; 2012 Jun; 18(5):567-71. PubMed ID: 22445250 [TBL] [Abstract][Full Text] [Related]
34. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo. Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621 [TBL] [Abstract][Full Text] [Related]
35. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA). Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487 [TBL] [Abstract][Full Text] [Related]
36. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry. Pyatigorskaya N; Sharman M; Corvol JC; Valabregue R; Yahia-Cherif L; Poupon F; Cormier-Dequaire F; Siebner H; Klebe S; Vidailhet M; Brice A; Lehéricy S Mov Disord; 2015 Jul; 30(8):1077-84. PubMed ID: 26011561 [TBL] [Abstract][Full Text] [Related]
37. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers. Majbour NK; Aasly JO; Hustad E; Thomas MA; Vaikath NN; Elkum N; van de Berg WDJ; Tokuda T; Mollenhauer B; Berendse HW; El-Agnaf OMA Transl Neurodegener; 2020 May; 9(1):15. PubMed ID: 32375873 [TBL] [Abstract][Full Text] [Related]
38. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203 [TBL] [Abstract][Full Text] [Related]
39. Activation of Lrrk2 and α-Synuclein in substantia nigra, striatum, and cerebellum after chronic exposure to arsenite. Drobna Z Toxicol Appl Pharmacol; 2020 Dec; 408():115278. PubMed ID: 33053406 [TBL] [Abstract][Full Text] [Related]